Ann: Second Cancer Patient Completes Course With Stable Disease, page-34

First 34 Last

Share
Profile

Follow
Investing101

2,667 Posts.

111

05/03/15

19:56

Post #: 14867685
Share

Originally posted by fever2tell ↑

Biotech Daily
Thursday March 5, 2015

Pharmaust says the second patient in its trial of PPL-1 for cancer has completed the 28-
day treatment at the lowest dose without material adverse events and with stable disease.
Pharmaust said that the Royal Adelaide Hospital patient had bowel cancer and the drug
was “well-tolerated, without material adverse events and the patient ... had stable disease
on completion of the treatment” as determined by computed tomography scan.
The company said that subject to the third patient in the low-dose group completing the
treatment schedule by mid-March, the trial would move to higher doses.
Pharmaust said that in parallel to monitoring patients who had completed the full 28-day
trial period, it was monitoring levels of the biomarker P70S6K in all patients who received
PPL-1 and had stayed on therapy for at least three days.
The company said that a number of patients had to be withdrawn due to reasons
unrelated to the study drug.
Pharmaust said that PPL-1 appeared to define “a new and unexpected mechanism of
action representing a potentially new class of anti-cancer drug”.
The company said that PPL-1 influenced the mammalian target of rapamycin (mTOR)
pathway, but, unlike other mTOR drugs, like Novartis’ Afinitor, or everolimus, and Pfizer’s
Sirolimus or rapamycin, it appeared to have very low toxicity.
Pharmaust said that PPL-1 had not shown an adverse event profile commonly associated
with conventional anti-cancer drugs, the lowest dose of PPL-1 had shown meaningful
reductions in the cancer marker P70S6K and PPL-1 targetted a biochemical pathway that
affected a range of regulatory mediators, without the side effect profile of other mTOR
drugs currently on the market.
Pharmaust was unchanged at 0.8 cents with 4.8 million shares traded.

Expand

Theres a small bit of promotion for us!

PAA Price at posting: 0.8¢ Sentiment: Buy Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

TLX

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

RNU

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

TX3

Canadian fieldwork yields multiple pegmatites for Trinex

AUG

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

There are more pages in this discussion • 1 more message in this thread...

First 34 Last

Add PAA (ASX) to my watchlist

(20min delay)
Last 21.0¢		Change 0.015(7.69%)		Mkt cap ! $87.89M

Open	High	Low	Value	Volume
20.0¢	21.0¢	19.5¢	$246.8K	1.218M

Buyers (Bids)

No.	Vol.	Price($)
2	17543	20.5¢

Sellers (Offers)

Price($)	Vol.	No.
21.0¢	130498	3

View Market Depth

No.	Vol.	Price($)
2	17543	0.205
4	180000	0.200
10	320742	0.195
17	612584	0.190
24	1078524	0.185

Price($)	Vol.	No.
0.210	130498	3
0.215	233021	5
0.220	140096	3
0.225	62500	1
0.230	51179	1

Last trade - 13.22pm 11/07/2024 (20 minute delay)

PAA (ASX) Chart

Ann: Second Cancer Patient Completes Course With Stable Disease, page-34

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Canadian fieldwork yields multiple pegmatites for Trinex

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Second Cancer Patient Completes Course With Stable Disease, page-34

Top Stories

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Canadian fieldwork yields multiple pegmatites for Trinex

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News